A CD4+CD161+ T-Cell Subset Present in Unexposed Humans, Not Tb Patients, Are Fast Acting Cells That Inhibit the Growth of Intracellular Mycobacteria Involving CD161 Pathway, Perforin, and IFN-γ/Autophagy

It remains undefined whether a subset of CD4+ T cells can function as fast-acting cells to control Mycobacterium tuberculosis (Mtbc) infection. Here we show that the primary CD4+ CD161+ T-cell subset, not CD4+CD161-, in unexposed healthy humans fast acted as unconventional T cells capable of inhibiting intracellular Mtbc and BCG growth upon exposure to infected autologous and allogeneic macrophages or lung epithelial A549 cells. Such inhibition coincided with the ability of primary CD4+CD161+ T cells to rapidly express/secrete anti-TB cytokines including IFN-γ, TNF-α, IL-17, and perforin upon exposure to Mtbc. Mechanistically, blockades of CD161 pathway, perforin or IFN-γ by blocking mAbs abrogated the ability of CD4+CD161+ T cells to inhibit intracellular mycobacterial growth. Pre-treatment of infected macrophages with inhibitors of autophagy also blocked the CD4+CD161+ T cell-mediated growth inhibition of mycobacteria. Furthermore, adoptive transfer of human CD4+CD161+ T cells conferred protective immunity against mycobacterial infection in SCID mice. Surprisingly, CD4+ CD161+ T cells in TB patients exhibited a loss or reduction of their capabilities to produce perforin/IFN-γ and to inhibit intracellular growth of mycobacteria in infected macrophages. These immune dysfunctions were consistent with PD1/Tim3 up-regulation on CD4+CD161+ T cells in active tuberculosis patients, and the blockade of PD1/Tim3 on this subset cells enhanced the inhibition of intracellular mycobacteria survival. Thus, these findings suggest that a fast-acting primary CD4+CD161+T-cell subset in unexposed humans employs the CD161 pathway, perforin, and IFN-γ'autophagy to inhibit the growth of intracellular mycobacteria, thereby distinguishing them from the slow adaptive...
responses of conventional CD4+ T cells. The presence of fast-acting CD4+CD161+ T-cell that inhibit mycobacterial growth in unexposed humans but not TB patients also implicates the role of these cells in protective immunity against initial Mtb infection.

Keywords: CD4+CD161+ T cells, killing intracellular bacteria, IFN-γ, perforin, tuberculosis

INTRODUCTION

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains the top killer among infectious diseases largely due to epidemics of HIV/AIDS and drug resistance (1). The World Health Organization estimates that there are 10.4 million new cases and 1.7 million deaths annually, including 0.4 million deaths in people with HIV infection (2). Vaccines usually provide one of the most cost-effective interventions to prevent death and morbidity from infectious diseases. Nevertheless, the current TB vaccine, Bacille Calmette–Guérin (BCG), only protects young children from severe disseminated TB, but not effectively protects against pulmonary TB in adults or drug-resistant TB (3, 4). The development of a better TB vaccine or vaccination approach requires precisely elucidating protective immune mechanisms in humans.

Protective immune mechanisms against TB infection remain largely undefined (5). The current paradigm underscores the important role for CD4+ T cells in mounting adaptive anti-TB immunity (6, 7). HIV/AIDS depletes CD4+ T cells increasing TB susceptibility and severity (8), although it is not known about the relative importance of HIV immune suppression versus CD4+ T-cell decline. Concurrently, studies in mice indicate that CD4+ T cells are required for immunity against high-dose Mtb infection (9–11). CD4+ T cells can evolve into Th1 effector cells producing IFN-γ/TNF-α for macrophage activation and subsequent control of TB infection (12). CD4+ Th17 immunity is also implicated in animal models of vaccination and TB (13, 14). It is also noteworthy that IFN-γ-independent CD4+ T-cell immunity to TB has been reported (15, 16). On the other hand, Ag-activated CD4+ T effector cells generated from exposed or infected individuals can function as cytotoxic T cells producing cytotoxic granules or inhibiting of intracellular Mtb bacilli (17, 18). However, the phenotypes and functional mechanisms of CTL-like CD4+ T-cell immunity are unclear.

As opposed to slow-acting adaptive CD4+ T cells responses, a fast-acting CD4+ T-cell subset that controls very early Mtb infection was implicated in our mechanistic study in nonhuman primates (NHP) (19). In this NHP study, we demonstrated that the depletion of CD4+ T cells by anti-CD4 mAb treatment led to very early Mtb dissemination (bacteremia) after pulmonary infection (19). This “early-protecting” CD4+ T-cell subset appeared to be different from slow conventional CD4+ T cells, as losses of the slow/late adaptive anti-TB immunity and T helper functions were seen in the late phase of CD4 depletion at endpoint 2 months after Mtb infection (19).

To date, it remains unknown whether primary CD4+ T-cell population in unexposed humans comprise a fast-acting unconventional T-cell subset that inhibit intracellular Mtb growth or control initial Mtb infection (19, 20). It is noteworthy that three major types of unconventional T cells: MAIT, iNKT and γδ T cells share expression of CD161 (21, 22). We therefore tested the hypothesis that primary CD4+ T cells expressing CD161 may be consistent with the early protective CD4+ T-cell subset implicated in our NHP study (19). Here, we demonstrated that a primary CD4+CD161+ T-cell subset, not CD4+CD161- T cells, in unexposed healthy donors, fast acts as unconventional T cells capable of inhibiting intracellular Mtb growth and controlling mycobacterial infection. We also illustrated the mechanism whereby the CD4+CD161+ T-cell subset inhibits mycobacterial growth, and found a loss of this mechanism in active TB patients.

MATERIALS AND METHODS

Ethics Statement

The protocols for use of human blood samples for experimental procedures were evaluated and approved by institutional review boards for human subjects’ research and institutional biosafety committees at Shanghai Pulmonary Hospital. All subjects were adults and anonymized, signed written informed consents.

Study Subjects

Unexposed healthy controls (average age 35.7 years, 13 males, 7 females) recruited in this study had records of BCG vaccination at birth without any history and evidence of TB or LTBI as shown by clinical evaluations and T-SPOTS (QuantiFERON test). Active TB patients (average age 46.5 years, 12 males, 8 females) were confirmed by positive culture of M. tuberculosis, radiological findings, and clinical symptoms. In another pilot study, three active TB patients were recruited. Among all participants, there is no evidence for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection and other infectious diseases or cancers.

Cell Culture and Reagents

THP-1 cells (Cell Bank, Chinese Academy of Sciences) were grown in RPMI 1640 (Gibco) supplemented and 10% heat-inactivated fetal bovine serum (FBS, Gibco). Prior to infection, THP-1 cells were treated with 50 ng/ml Phorbol 12-myristate 13-actate (PMA, Sigma-Aldrich) for 48 h to induce differentiation into macrophages, then washed three times with pre-warmed PBS and maintained in antibiotic-free media at 37°C for further use.

Human peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque PLUS medium (GE) from buffy coats prepared from the peripheral blood of healthy donors (from Blood Center of Shanghai Changhai
hospital) or from peripheral blood from active TB patients in Shanghai Pulmonary Hospital. Adherent-monocytes were enriched by adherence on plastic culture plates for 2 h. Non-adherent cells were removed via vigorous washing using pre-warmed PBS three times. Human monocytes-derived macrophages (hMDM) were differentiated from adherent-monocytes in media containing RPMI1640 (Gibco), supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco) and 50 ng/ml human M-CSF (Novoprotein) for 7 days.

The following neutralization antibodies and their corresponding isotype controls were used in antibody blocking assays: anti-human TNF-α (Clone 28401, R&D) and its isotype control (Clone 11711, R&D); anti-human IFN-γ (Clone 25718, R&D), anti-human perforin (Clone 1001103, R&D) and its isotype control (Clone 20102, R&D); anti-human IL-17 (AF-317, Polyclonal Goat IgG, R&D), anti-human granulysin (Polyclonal Goat IgG) and its isotype control (AB-108,R&D); anti-human FasL (Clone NOK-1,Biolegend) and its isotype control (Clone MOPC-21, Biolegend); anti-human PD1 (Clone EH12.2H7, Biolegend), and anti-human Tim3 (Clone F38-2E2, Biolegend). The blocking antibodies to CD161 were purchased from BD (Clone DX12) and Miltenyi (Clone 191BB) respectively. Autophagy inhibitor, 3-MA, was purchased from Beyotime.

**Purification of CD4+CD161+ cells, CD4+CD161-Cells and CD20+B Cells**

CD4+ T cells were enriched from PBMC of healthy donors or active TB patients by negative selection method using CD4+ T Cell Isolation Kit II from Miltenyi (130-096-533). Then, CD4+ T cells were stained with anti-human CD161-APC (BD, 550968), followed by anti-APC magnetic beads (Miltenyi Biotech, 130-090-855) for secondary positive purification. Cells were loaded onto columns and the passing cells were collected as CD4+CD161- T cells, CD4+CD161+ T cells were released from columns using release buffer (Miltenyi Biotech). There was no evidence for significant activation of CD4+CD161+ T cells after purification (data not shown). B cells were positivity isolated from PBMC using anti-CD20 microbeads from Miltenyi Biotech according to the manufacturer’s instructions. Cell purity was consistently ≥96% as demonstrated in Supplementary Figure 1A.

**Mycobacteria Culture, Infection of Cells and Quantification of Intracellular Mycobacterial Growth**

*Mycobacterium bovis*, Bacillus Calmette-Guerin (BCG) and *M. tuberculosis* H37Rv were grown into log phase at 37°C in Difco Middlebrook 7H9 broth medium (Becton Dickinson) with 10% oleic acid-albumin-dextrose-catalase (OADC) Enrichment (Becton Dickinson). 0.05% (v/v) Tween 80 and 0.2% (v/v) glycerol. Basically, cells were infected with BCG at a multiplicity-of-infection (MOI) of 10 bacilli to one cell overnight served as target cells. Human monocyte-derived macrophage (hMDM) cells were infected with H37Rv at a MOI of four for 4 h. After infection, extracellular non-internalized bacilli were removed by washing with pre-warmed PBS four times. Then, 1 X 10⁹ mycobacteria-infected THP-1, A549, or hMDM cells were co-cultured with purified CD4+CD161+/CD4+ CD161- T and B cells at a ratio of 1:10 in the presence or absence of neutralization Abs (5 ug/ml) and their isotype controls, or inhibitors (inhibitors were pre-incubated with cells for 2 h) in 200 ul media without antibiotic in 96-well-plates for 3 days. Then, wells were aspirated, and the infected cells were lysed in 200 ul of sterile PBS with 0.067% SDS. A 10-fold serial dilution was performed for quantitative measurement of viability. 100 ul of aliquots were plated in triplicate on Middlebrook 7H10 or 7H11 agar plates supplied with 10% OADC for 2–3 weeks until colonies were large enough to be counted. The percentage Survival index (23) represented as intracellular bacteria survival was calculated as follows: Survival index = 100 x CFU of co-cultured group/CFU of infected group.

**Adoptive Transfer of CD4+CD161+ and CD4+CD161- T Cells to BCG-Infected SCID Mice**

Four-week-old female SCID mice (Shanghai SLAC Laboratory Animal) were infected intravenously via the tail vein with 1 x 10⁷ CFU of BCG in 0.2 ml PBS. After 3 days, 5 x 10⁵ sorted human CD4+CD161+ T cells, CD4+CD161- T cells or PBS were transferred into BCG-infected recipient mice (n=8 for each group) in 0.2 ml PBS through intravenously via the tail vein. At day 25 post-infection, the lungs of all mice were harvested, homogenized in PBS, and plated on 7H10 agar at 10-fold series dilution to enumerate BCG bacilli.

**Flow Cytometry Analysis**

For cell frequency analysis, cells were incubated with PB-anti-CD3 (SP34-2, BD), FITC-anti-CD4 (SK3, BD), BV605-anti-CD161 (HP3G8, Biolegend). For analysis of the cell memory state, cells were incubated with PB-anti-CD3 (SP34-2, BD), FITC-anti-CD4 (SK3, BD), BV605-anti-CD161 (HP3G8, Biolegend), BV711-anti-CCR7 (G043H7, Biolegend), PE/Cy7-anti-CD45RA (HI100, Biolegend) for 20 min at room temperature in dark. For phenotyping of special surface markers, cells were incubated with PB-anti-CD3 (SP34-2, BD), FITC-anti-CD4 (7A5, Thermo Scientific), APC-anti-CD161 (B6, Biolegend), AF700-anti-Tim-3 (J418F1, Biolegend), BV605-anti-PD-1 (TS1/18, Biolegend) for 20 min at room temperature in dark. For functional assay, PBMC were stimulated with PMA (50 ng/ml) + ionomycin (1 µg/ml) (1 h) and brefeldin A (10 µg/ml) were added for 5 h. Cells were stained with monoclonal antibodies to the surface markers, PB-anti-CD3 (SP34-2, BD), FITC-anti-CD4 (SK3, BD), BV605-anti-CD161 (HP3G8, Biolegend), for 30 min at room temperature in the dark. After washing twice, cells were fixed in fixation/permeabilization buffer (BD), followed by intracellular cytokine staining with antibodies, BV711-anti-IFN-γ (4S.B3; Biolegend), PE/Cy7-anti-TNF-α (Mab11, Biolegend). For detection of perforin, PBMC were stimulated with BCG-infected hMDM cells for 8 h and brefeldin A (10 µg/ml) added for the last 4 h. Cells were stained with monoclonal antibodies to the surface markers, PB-anti-CD3 (SP34-2, BD), BV510-anti-CD4 (SK3, BD), BV605-anti-CD161 (HP3G8, Biolegend), for 30 min on ice in the dark. After washing twice, cells were fixed using fixation/permeabilization buffer (BD),
followed by intracellular cytokine staining with FITC-anti-perforin (dG9; Biolegend). Then cells were acquired on an LSR Fortessa flow cytometer (BD), and the data were analyzed with FlowJo software (TreeStar).

**Quantification of Gene Expression by RT-qPCR**

Sorted CD4+CD161+ orCD4+CD161- T cells from healthy controls were co-cultured with BCG-infected hMDM for 24 h. RNA isolation from isolated cells, reverse-transcription and PCR reactions were done as described in (24). Primers for IFNG, PRF and EF1A were reported in (25). Other primers used for amplification in this study were synthesized from Sangon Biotech: IL17A-F,5'-CGGACTGTGATGGTCAACCTGA-3', IL17A-R, 5'-GCACCTTGCTCCAGATCAACA-3'; FASLG-F, 5'-GGTTCTGTGTGCTTGTAGGA-3', FASLG-R, 5'-CTGTGTGTCATCTGGCTGGTAGA-3'. EF1A was used as a reference control. Fold change was calculated with the ΔΔCT method.

**Measuring Secretory Cytokines Using ELISA**

The amounts of IFN-γ and IL-17A in cell supernatants were detected using human cytokine ELISA kit (C608 for Human IFN-γ; C623 for Human IL-17A; Genstar) according to the manufacturer’s instructions.

**LC3B Staining**

Cells were then fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.2% Triton X-100/PBS for 10 min, and pre-blocked in 5% BSA/PBS overnight. The cells were then incubated with rabbit LC3B antibody that was diluted at 1/100 in blocking solution for 2 h, washed three times with PBS, and incubated with Alexa fluor 488-conjugated anti-rabbit IgG Ab (1/200 in blocking solution) for 1 h. After washing with PBS, the cells were further incubated with 10 μg/ml Hoechst stain for 20 min, and then used for confocal microscopy (Zeiss, German) analysis.

**Statistical Analysis**

Statistical analysis was performed with GraphPad Prism 6.0. Differences between groups were assessed by t test, nonparametric t test, or one-way ANOVA, followed by the Dunnett’s test or Tukey’s multiple comparison test indicated in each figure.

**RESULTS**

A Primary CD4+CD161+ T-Cell Subset, Not CD4+CD161- T Cells, From Unexposed Healthy Humans Inhibited Intracellular Mycobacterial Growth in Infected Autologous and Allogeneic Macrophages as Well as Lung Epithelial Cells

Our recent CD4 depletion studies in NHPs suggest that CD4+ T cells contain a fast-acting T-cell subpopulation which is required to control very early Mtb dissemination after pulmonary infection (19). Notably, human CD161 is considered to be a surrogate marker of unconventional T cells, as it is expressed on three major types of such T cells: MAIT, iNKT and gamma delta T cells (21, 22). In addition, CD161 expression on an Foxp3+ Treg subset allows for the innate production of IL-17 and other pro-inflammatory cytokines (26, 27). Since NHPs closely resemble humans, we hypothesized that human CD4+CD161+ T cells may represent the fast-acting CD4+ T-cell subset required to control early Mtb dissemination after pulmonary infection in NHPs (19). To test this hypothesis, we assessed CD4+CD161+ T cells for the ability to inhibit intracellular Mtb growth using an in vitro infection model as described by us and others (23, 28). Thus, CD4+CD161+ T cells and controls, CD4+CD161- T and CD20+ B cells, were purified from PBMC of unexposed healthy humans using immune-magnetic bead-based standard methods. The isolated cell subsets were shown to be ≥96% pure (Supplementary Figure 1A). Then, CD4+CD161+ T cells, as well as control CD4+CD161- T cells and B cells, were co-cultured, respectively, with Mtb-infected autologous monocyte-derived macrophages (hMDM) at a ratio of 10:1 for 3 days. Strikingly, CD4+CD161+ T cells, but not the CD4+CD161- T cell control, significantly inhibited intracellular Mtb growth in infected autologous hMDM (Figure 1A). We then employed M. bovis BCG-infected target cells for subsequent mechanistic experiments, as studies published by us and peers showed that T effector cells capable of restricting intracellular BCG replication can also similarly inhibit intracellular Mtb growth (29–31). While CD4+CD161+ T cells, not controls, similarly mediated growth inhibition of BCG and Mtb in infected autologous hMDM (Figures 1A, B), they also inhibited intracellular BCG growth in the THP-1 human macrophages (Figure 1C). Concurrently, CD4+CD161+ T cells also inhibited intracellular BCG growth in BCG-infected A549 lung cells as well (Figure 1D). Since CD4+CD161+ T cells were derived from healthy donors express potential MHC II different from THP-1 or A549 target cells, such mismatches implicate that CD4+ CD161+ T-cell inhibition of intracellular mycobacteria does not likely require MHC II-restricted antigen recognition. Taken together, these results suggest that primary CD4+CD161+ T-cell subset differ from CD4+CD161- T cells in the ability to directly inhibit mycobacterial growth in both autologous and allogeneic target cells.

**CD4+CD161+ T-Cell-Mediated Inhibition of Mycobacterial Growth Coincided With the Rapid Expression of Anti-TB Cytokines Including IFN-γ, TNF-α, IL-17A and Perforin**

The expression of CD161 on CD4+ T cells is implicated as a marker of Th17 cells producing IL-17 upon stimulation with cytokines and TCR engagement (32), but also is linked to IFN-γ production (33). However, it is not known whether CD4+CD161+ T cells could secrete anti-TB cytokines upon encountering infected target cells. Whether such secretory cytokines lead to mycobacterial growth inhibition is also not known. To address these questions, primary CD4+CD161+ T cells or CD4+CD161-
controls were co-cultured with BCG-infected hMDM for 24 h, and then assessed supernatants for expression/production of anti-TB cytokines. Indeed, CD4+CD161+ T cells expressed significantly higher levels of IFN-γ and IL-17 transcripts than CD4+CD161- cells (Figure 2A). Concurrently, CD4+CD161+ T cells also expressed much higher levels of antimicrobial CTL-related molecules perforin and Fas ligand than did CD4+CD161- controls (Figure 2A). We found that cultured CD4+CD161+ T cells, but not CD4+CD161-controls, secreted large amounts of IFN-γ and IL-17 cytokines in the day 3 supernatants (Figure 2B). Particularly, the level of secreted IFN-γ was almost 1,500 pg/ml high, 5 times higher than IL-17, suggesting that CD4+CD161+ T cells were Th1 dominant upon the exposure. To define this Th1 phenotype, we measured IFN-γ- and TNF-α-producing CD4+CD161+ T cells using intracellular cytokine staining after stimulation with PMA and ionomycin. Intracellular cytokine staining demonstrated that >23% of CD4+CD161+ T cells showed the Th1 phenotype producing anti-TB cytokines IFN-γ and IFN-α, whereas CD4+CD161- T cells exhibited a much lower Th1 frequency (Figure 2C, Supplementary Figure 1B).

**Perforin and IFN-γ Produced by CD4+CD161+ T Cells Were Required to Inhibit Intracellular Mycobacterial Growth, Involving Autophagy in Infected hMDM**

We then sought to determine which of the cytokines produced by CD4+CD161+ T cells contributed to the inhibition of intracellular mycobacterial growth in infected target cells. To
address this, we performed blocking experiments using neutralizing anti-cytokine antibodies in the intracellular mycobacterial inhibition assay. To our surprise, blockade of IFN-γ and perforin could significantly reverse or abrogate the ability of primary CD4+CD161+ T cells to inhibit intracellular mycobacterial growth in infected hMDM (Figures 3A, B). However, neutralization of IL-17, TNF-α or Fas-L had little or no effects on the observed inhibition (Figures 3C–F). Adding anti-granulysin blocking Ab to the co-culture did not alter the inhibition, as CD4+CD161+ T cells produced no or low-level granulysin (Figure 3E and data not shown).

Recent studies showed that IFN-γ could activate selective autophagy leading to inhibition of mycobacteria in infected hMDM (34). We therefore examined whether the selective autophagy process played a role in IFN-γ-producing CD4+CD161+ T-cell inhibition of intracellular mycobacteria in hMDM. In order to block autophagy, we preincubated hMDM prior to coculture with CD4+CD161+ T cells with 3-MA, which has been shown to inhibit autophagy sequestration (35). Notably, the 3-MA pre-treatment of BCG-infected hMDM significantly blocked the CD4+CD161+ T-cell restriction of intracellular mycobacterial growth, as compared to the DMSO control (Figure 4A). In parallel, we also found less LC3B puncta in the co-cultures with the 3-MA pre-treated hMDM (Figures 4B, C). Consistently, the addition of CD4+CD161+ T cells resulted in more LC3B puncta in hMDM as compared to the addition of CD4+CD161- T cells (Figures 4B, C). These results suggest that perforin and IFN-γ produced by CD4+CD161+ T cells act in concert to inhibit intracellular mycobacterial growth, involving downstream selective autophagy in infected macrophages.

**CD161 Blockade Reduced the Ability of CD4+CD161+ T Cells to Inhibit Intracellular Mycobacterial Growth**

The CD161 ligand, Letin-like transcript 1 (LLT1), is expressed on monocytes/macrophages and DC, and LLT1/CD161 signaling has been shown to stimulate Th1 differentiation (36). We hypothesized that the CD161 signal pathway contributes to the observed fast-acting antimicrobial function of CD4+CD161+ T cells. To test this hypothesis, we performed CD161 blocking

---

**FIGURE 2 |** CD4+CD161+ T cell-mediated inhibition of mycobacterial growth coincided with the ability to rapidly express anti-TB cytokines including IFN-γ, TNF-α, IL-17A and perforin. Bar graph (A) shows the fold changes in expression levels of individual anti-TB cytokine genes in CD4+CD161+ T cells and CD4+CD161- controls co-cultured for 24 h with autologous BCG-infected hMDM determined by RT-qPCR. Data shown as mean ± SD are derived from five experiments. "***p < 0.0001, "**p < 0.001, "*p < 0.05 (t test). Bar graph (B) shows the means ± SD values of secreted IFN-γ and IL17A in the supernatant from the BCG-infected hMDM culture, theCD4+CD161+ T cell plus BCG-infected hMDM co-cultures and theCD4+CD161- plus infected hMDM co-culture. Data are pooled from 15 healthy donors. "***p < 0.0001 vs. Media group (ANOVA, Dunnett’s test). Bar graph (C) shows flow cytometry frequency data from ICS assay indicating thatCD4+CD161+ T cells exhibited stronger capability of producing Th1 cytokines IFN-γ and TNF-α. PBMC isolated from unexposed healthy donors (n=15) were stimulated with PMA/ionomycin, then stained intracellularly for IFN-γ and TNF-α. "***p < 0.0001 (t test). The representative flow cytometry histograms with gating plots were presented in Supplementary Figure 1B.
experiments using anti-CD161 neutralizing antibodies from two commercial sources. The neutralization activities of these two anti-CD161 antibodies have been documented in early reports (36). Interestingly, we found that antibody blockade of the CD161 pathway indeed reversed the CD4+CD161+ T-cell inhibition of BCG growth in infected hMDM (Figure 5).

These results suggest that CD161 signaling pathway play a role in the mycobacterial growth inhibition in infected macrophages.

**Adoptive Transfer of Human CD4+CD161+ T Cells Conferred Protective Immunity Against Mycobacterial BCG Infection in SCID Mice**

Based on the *in vitro* findings as defined above, we hypothesized that CD4+CD161+ T cells can function as fast-acting T cells to control mycobacterial infection *in vivo*. To test this hypothesis, we developed a cell adoptive transfer strategy using BCG-infected SCID mice as a model (Figure 6A). CD4+CD161+ and CD4+CD161- T cells were purified from PBMCs of unexposed healthy donors, and then adoptively transferred to SCID mice at day 3 after BCG infection (Figure 6A). This proof-of-concept study was focused on the immune control of bacillary burden after infection, as our recent NHP work demonstrated that this CD4+ T-cell subset is required to control very early Mtb dissemination (19). Interestingly, mice infused with CD4+CD161+ T cells showed significantly lower bacterial burdens in lungs, compared with control mice receiving CD4+CD161- T cells or PBS (Figure 6B). Thus, CD4+CD161+ T cells, but not the CD4+CD161- T cell control, can confer immune control of mycobacterial infection in SCID mice. These findings suggest that CD4+CD161+ T cells play a role in protective immunity against mycobacterial infection *in vivo*. 

**FIGURE 3** | Perforin and IFN-γ produced by CD4+CD161+ T cells were required to inhibit intracellular mycobacterial growth. (A–F) Two panels of bar graphs show the effect of anti-cytokine neutralization Abs on CD4+CD161+ T-cell inhibition of intracellular BCG growth. Shown are mean survival indexes ± SD for BCG bacilli in infected hMDM (Media only) and CD4+CD161+ T cells (+ DP T cells) plus infected hMDM co-cultured for 72 h at a ratio of 10:1 in the absence or presence of anti-IFN-γ, anti-IL-17A, anti-TNF-α, anti-perforin, anti-granulysin, anti-FasL Abs, and corresponding Ig isotype controls, respectively (5 μg/ml for each). Note that only the anti-IFN-γ and anti-perforin blockades in the co-culture system could reverse the CD4+CD161+ T-cell-mediated inhibition of mycobacterial growth. Data shown as mean ± SD are derived from five experiments using 12 healthy donors for preparing hMDM. ****p < 0.0001, ***p < 0.001, **p < 0.05, ns, not significant (ANOVA, Tukey’s test).
Circulating CD4+CD161+ T Cells From TB Patients Failed to Inhibit Intracellular Mycobacterial Growth, Which Was Linked to a Reduced Ability to Produce IFN-γ and Perforin

Finally, we sought to examine whether there were alternations in the phenotype and function of CD4+CD161+ T cells in ATB patients. Consistent with the decreased CD161 expression in CD4+ T cells in ATB cohorts (37), the frequency of CD4+CD161+ T cells in the blood of ATB patients was significantly lower than those in healthy controls (Figure 7A, Supplementary Figure 1C). Notably, of the primary CD4+CD161+ T cells in both ATB patients and healthy controls, the majority, ~80 and ~95%, respectively, displayed the CCR7-CD45RA- effector memory (EM) T cell phenotype (Figure 7B, Supplementary Figure 1C). CD4+CD161+CCR7-CD45RA- central memory (CM) T cells accounted for ~15 and ~10%, of the CD4+CD161+ T cells, respectively, in ATB patients and healthy controls (Figure 7B, Supplementary Figure 1C). Interestingly, CD4+CD161+ T cells in ATB patients showed significantly higher expression of check-point inhibitory receptors PD-1 and Tim-3 than those in healthy controls (Figure 7C, Supplementary Figure 1C).

Most importantly, CD4+CD161+ T cells from ATB patients displayed defects in the ability to inhibit intracellular...
mycobacterial growth in infected hMDM (Figure 7D).
Consistently, CD4+CD161+ T cells in ATB patients showed the reduced ability to produce IFN-\(\gamma\) and perforin upon exposure to mycobacterium-infected hMDM (Figure 7E, Supplementary Figure 1C), while these two cytokines proved to be critical for the CD4+CD161+ T-cell mediated growth inhibition of intracellular mycobacteria (Figure 3). Of note, the blockade of PD1 or Tim3 resulted in ~30% decrease of BCG counts (Supplementary Figure 1C).

Taken together, these results suggest that CD4+CD161+ T cells sorted from ATB patients displayed defective production of IFN-\(\gamma\) and perforin, leading to impaired antimicrobial activity against mycobacteria.

**DISCUSSION**

Our previous work demonstrated a role for fast-acting CD4+ T cells in containing acute Mtb replication and extrapulmonary dissemination at the early stage of pulmonary TB infection (19), yet the identity of the protective T cell subpopulation or its mechanism of action were not elucidated. Here, we identified a fast-acting CD4+CD161+ T-cell subset in unexposed healthy humans capable of rapidly producing anti-TB cytokines and inhibiting intracellular Mtb growth. Mechanistically, the fast-acting CD4+CD161+ T-cell subset inhibit/kill intracellular mycobacteria in infected macrophages via the CD161 pathway, as well as release of perforin and IFN-\(\gamma\) involving autophagy distinguishing themselves from the slow adaptive/conventional CD4+ T cells not expressing CD161. These findings are clinically relevant as CD4+CD161+ T-cells in TB patients exhibit a loss or reduced the ability to inhibit the growth of intracellular mycobacteria as well as to produce perforin and IFN-\(\gamma\). These data define CD4+CD161+ T cells as a human T cell subpopulation with the capacity to act as an early protective CD4+ T-cell subset as implicated in NHP.

Published studies have shown that CD4+ T effector cells in exposed or vaccinated individuals can express perforin/FasL and exert CTL-like activities against viral infections (38–41). Concurrently, Mtb-activated CD4+ T effector cells generated from tuberculin skin test-positive persons can mediate perforin/FasL-independent inhibition of intracellular Mtb (18). Extending those published studies, here we illustrate that anti-Mtb primary CD4+ T cells can exist even in unexposed healthy humans and that such Mtb-inhibiting primary CD4+ T cells are the CD4+CD161+ subset rather than other CD4+ T cells not expressing CD161. In addition, we also define immune mechanisms...
whereby the CD4+CD161+ T-cell subset activate and inhibit the growth of intracellular mycobacteria upon exposure to infected target cells. Notably, unexposed healthy donors in our study are adult humans without evidence of LTBI, and the MHC-unrestricted inhibition of Mtb by primary CD4+CD161+T cells would not be simply attributed to the decades-long memory phenotype of primary CD4+CD161+ T cells in unexposed healthy humans may not necessarily represent decades-long memory responses to BCG. This notion is supported by our results demonstrating that the CD4+CD161+T-cell subset can inhibit intracellular mycobacteria in the infected MHC II-mismatched allogeneic macrophages and lung epithelia cells. On the other hand, the CD4+CD161+ T-cell subset can act like other unconventional T-cell populations MAIT, NKT and Vγ2Vδ2 T cells (21, 22) to produce wide-spectrum cytokines including perforin, IFN-γ, TNF-α, and IL-17. Notably, high-frequency CD4+CD161+T cells are noted in unexposed individuals, but most of them are not the unconventional NKT cells as revealed by αGal-loaded CD1d tetramer (data not shown). It is also worth to mention that anti-TB cytokines produced by the CD4+CD161+ T-cell subset can certainly contribute to protective immunity against very early Mtb infection as seen in NHP and human resisters (16, 19), while only perforin and IFN-γ are required for the ability of CD4+CD161+T-cells to inhibit the growth of intracellular mycobacteria.

Mechanisms whereby CD4+CD161+ T cells inhibit intracellular mycobacteria appear to involve multiple immune events. The results in the CD161 blockade implicate that CD161 binding to
the LLT1 ligand on infected macrophages can bring proximity between CD4+CD161+ T cells and target cells for immune activation and subsequent anti-TB cytokine actions. In fact, previous data has shown that the interaction of LLT1 and CD161 resulted in the production of IFN-γ in T cells (36). However, this hypothesis needs more data to prove. Moreover, the mechanism of how CD4+CD161+ T cells sensed mycobacteria-infected macrophages is unclear. Concurrently, the perforin-induced action may act in concert with IFN-γ-driven macrophage activation/autophagy leading to inhibiting mycobacteria (34). These hypothetical mechanisms are supported by our results derived from experiments using anti-CD161, anti-perforin or anti-IFN-γ blocking antibodies and autophagy inhibitors, respectively. It is also noteworthy that the IFN-γ action on infected macrophages can trigger IFN-γ-dependent selective autophagy leading to the control of intracellular mycobacteria (23, 34).

Given the fast-acting capabilities to produce anti-TB cytokines and inhibit intracellular mycobacteria, CD4+CD161+ T cells may play a role in protective immunity against initial Mtb infection. In fact, our recent NHP work has shown that an unconventional CD4+ T-cell subset is required to control very early Mtb dissemination after pulmonary infection (19). In addition, adoptive transfer of humanCD4+CD161+ T cells can confer protective immunity against BCG infection in SCID mice. Furthermore, our data in human TB patients implicate that a loss of the ability of CD4+CD161+ T cells to inhibit intracellular mycobacteria may contribute to the inefficient control of Mtb infection and development of TB.

Thus, the current study identifies and defines Mtb-inhibiting function and mechanisms of a fast-acting primary CD4+CD161+T-cell subset in unexposed healthy humans as well as dysfunction of this CD4+CD161+T-cell immunity mechanism in TB patients. Findings suggest that CD4+CD161+ T-cell subset may contribute to protection or sterilizing immunity against initial Mtb infection upon exposure in humans.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Human subjects’ research and institutional biosafety committees at Shanghai Pulmonary Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Human subjects’ research and institutional biosafety committees at Shanghai Pulmonary Hospital.

AUTHOR CONTRIBUTIONS

RY, HBS, WS and ZWC designed the project. RY, JP, YDL, LS, EZY, XNS, LY, YDL, and YP performed the experiments. RY, RM, HBS and ZWC analyzed the data and jointly wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by Chinese National Major Projects Grants (2018ZX01031001-006-001), National Natural Science Foundation of China (Grant No. 81901607, 31970876), Program for Outstanding Medical Academic Leader (No2019LJ13), and Clinical Research Plan of SHDC (NO.16CR1028B).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.599641/full#supplementary-material

SUPPLEMENTARY FIGURE 1 | Representative flow cytometry histograms show purity and effector functions of CD4+CD161+ T cells and controls isolated from unexposed healthy donors, as well as compare phenotypes of CD4+CD161+ T cells between ATB and HC groups and the specific staining of LC3B in BCG-infected hMDM. (A) Purity of cell subsets enriched by MACS methods used for mycobacteria inhibition assay. From Left to Right, enriched B cells, CD4+CD161- T cells and CD4+CD161+ T cells. (B). Representative flow cytometry histograms showing production of anti-TB cytokines (IFN-γ and TNF-α) by CD4+CD161+ and CD4+CD161- T-cell subsets after PMA + Ionomycin stimulation. (C). Representative flow cytometry histograms comparing frequencies of CD4+CD161+ T cells in blood between ATB and HC groups (Top-left), and the expression patterns of CD45RA,CCR7 (Lower-left) and PD-1, Tim-3 (Right) on gated CD4+CD161+ T cells. (D). Representative flow cytometry histograms measuring perforin-producing CD4+CD161+ T cells in PBMC from ATB and HC groups stimulated with BCG-infected hMDM. (E). Specific staining of LC3B puncta by LC3B Ab in hMDM. Fluorescence imaging of BCG-infected hMDM stained with rabbit-Isotype IgG Ab or rabbit LC3B Ab that was diluted at 1/100 in blocking solution for 2 h, washed three times with PBS, and incubated with Alexa fluor 488-conjugated anti-rabbit IgG Ab (1/200 in blocking solution) for 1 h. After washed with PBS, the cells were further incubated with 10 μg/ml Hoechst33342 for 20 min, and then used for confocal microscopy (Zeiss, German) analysis. White arrows indicate the LC3B puncta.

SUPPLEMENTARY FIGURE 2 | Blockade of PD1 or Tim3 enhanced anti-mycobacteria ability of CD4+CD161+ T cells from active tuberculosis patients. CD4+CD161+ T cells from patients with active tuberculosis (n=3) were cultured with BCG-infected THP-1 cells for 3 days under the treatment of Media, Isotype, anti-PD1 or anti-Tim3 antibodies were used at 5 μg/mL. Shown are mean survival indexes ± SD for BCG bacilli in each group. ***p < 0.0001, **p < 0.001 vs Isotype group (ANOVA, Dunnett’s test).

REFERENCES

1. Collaborators, G.B.D.C.o.D. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (2017) 390(10100):1151–210. doi: 10.1016/S0140-6736(17)32152-9

2. WHO. Global Tuberculosis Report 2017, The World Health Organization Annual Report. WHO (2017). Available at: http://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf.
40. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol (2012) 86(12):6792–803. doi: 10.1128/JVI.07172-11
41. Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4(+) T Cells, Their Differentiation and Function. Front Immunol (2017) 8:194. doi: 10.3389/fimmu.2017.00194
42. Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity (2009) 31(6):859–71. doi: 10.1016/j.immuni.2009.11.007
43. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol (2011) 12(6):647–71. doi: 10.1038/ni.2038
44. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 38(2):373–83. doi: 10.1016/j.immuni.2012.10.021

Conflict of Interest: RY was employed by Wuhan YZY Biopharma Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Peng, Pi, Liu, Yang, Shen, Yao, Shen, Modlin, Shen, Sha and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.